Aptorum Group Ltd
APM.O- Latest Trade
- trading lower1.3USD
- Change
- 0
- % Change
0.38%Negative
- Day Range
- 1.21 - 1.39
- 52-Week Range
- 0.86 - 3.34
As of Jun 29 2022. Values delayed up to 15 minutes
- Previous Close
- 1.30
- Open
- 1.37
- Volume
- 87,373.00
- 3 Month Average Trading Volume
- 2.13
- Shares Out (Mil)
- 35.64
- Market Cap
- 48.91
- Forward P/E
- -1.65
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 1 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 31.72
- Price To Book (Quarterly)
- 2.07
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.25
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -80.13
- Return On Equity (TTM)
- -81.99
2021 (millions USD)
About Aptorum Group Ltd
Company Information
Aptorum Group Limited is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's segments include Therapeutics and Non-Therapeutics. Therapeutics segment is seeking to develop various drug molecules (including projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment of human disease conditions to tackle unmet needs, in particular, two of its lead projects targeting infectious disease and cancer (including orphan oncology indications). Non-Therapeutics segment encompasses three businesses, such as diagnostics projects, including a molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology, natural supplements, including NativusWell, and AML Clinic.
Address
17 Hanover SquareLONDON,
W1S 1BN
United Kingdom
Industry
Biotechnology & Drugs
Executive Leadership
- Darren Lui
- President, Executive Director
- Ian Huen
- Chief Executive Officer, Founder, Executive Director
- Sabrina Khan
- Chief Financial Officer
- Angel Ng
- Chief Operating Officer
- Clark Cheng
- Chief Medical Officer and Executive Director
- Thomas Lee
- Head of Research and Development
- Douglas W. Arner
- Non-Executive Independent Director
- Charles Bathurst
- Non-Executive Independent Director
- Mirko Scherer
- Non-Executive Independent Director
- Justin Wu
- Non-Executive Independent Director
Latest News
- Markets3M, IBM, airline stocks
Wall Street futures fell on Tuesday as a selloff in technology stocks ahead of the Federal Reserve's policy meeting overshadowed upbeat results from blue-chip companies including IBM and 3M.
- MarketsBlue Apron, Baker Hughes, Luminar, cruise cos
U.S. stock indexes rose on Thursday on strong earnings reports, while bargain hunting boosted mega-cap growth companies after the Nasdaq index plunged into correction territory in the previous session.
- MarketsAmerican Airlines, Travelers, Chinese tech ADRs
U.S. stock futures rose on Thursday on a string of strong earnings led by American Airlines and insurer Travelers, a day after the tech-heavy Nasdaq plunged into correction territory.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,813.70 | -- |
| Copper | 694.25 | 1.57%Negative |
| Brent Crude Oil | 116.26 | -- |
| CBOT Soybeans | 1,674.25 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,818.83 | 0.07%Negative |
| Euro STOXX 50 | 3,514.32 | 0.99%Negative |
| FTSE 100 | 7,312.32 | 0.15%Negative |
| Nikkei 225 | 26,804.60 | -- |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes